Due to the dynamic and versatile characteristics of ischemic penumbra, selecting the right acute ischemic stroke (AIS) patients for revascularization therapy (RT) based on initial available imaging can be challenging. The main patient selection criterion for RT is the size of the mismatch between the potentially salvageable tissue (penumbra) and the irreversibly damaged tissue (core). The goal of revascularization RT is to "freeze" the core and prevent it from extending to the penumbral tissue. Penumbral imaging selection of AIS patients for RT, using magnetic resonance or CTbased studies, may provide more clinical benefit to the appropriate patients, although direct evidence is pending. Not all penumbra-core mismatches beyond 3 hours are equal and need treatment, and defining which mismatches to target for RT is the current goal of ongoing clinical trials. In addition to "penumbral"-based imaging, large vessel occlusion and clot length estimation based on CT angiography and noncontrasted ultrathin CT scan has been used to identify patients who are refractory to systemic thrombolysis and may be eligible for endovascular therapy. The application of various imaging modalities in selecting and triaging AIS patients for RT is discussed in this review. Larger prospective randomized trials are needed to better understand the role of various imaging modalities in selecting AIS patients for RT and to understand its influence on clinical outcome. Neurology Although acute ischemic stroke (AIS) is the leading cause of disability worldwide, treatment options for AIS remain limited to systemic and local revascularization therapies. Currently, the only US Food and Drug Administration-approved treatment for AIS is IV recombinant tissue plasminogen activator (rtPA), which must be administered within 3 hours of symptom onset.
1Results from the ECASS III trial have since expanded treatment to 4.5 hours; however, the majority of AIS patients still do not receive IV rtPA because of this narrow time window.2 Endovascular therapy (ET) may be considered for AIS patients for whom IV rtPA fails, who do not qualify for IV rtPA treatment, or who present beyond the IV rtPA time window. Despite the relatively high reported recanalization rate of ET (48% to 87%), good clinical outcome is limited to 25% to 41%. [3][4][5][6][7][8][9] One possible explanation of the discrepancy between recanalization and clinical outcome rates is the presence of variable sizes of salvageable brain tissue (penumbra) in the ischemic territory. Penumbra-based imaging, large-vessel occlusion, and clot length estimation based on CT angiography (CTA) and ultrathin noncontrasted CT (NCCT) head scanning have been used to identify patients who are refractory to systemic thrombolysis and may be appropriate for ET, thus potentially improving clinical outcome. Selecting patients on the basis of vessel occlusion and clot length is the main target for an ongoing clinical trial,